Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.bluebird bio (formerly Genetix Pharmaceuticals) and Genethon have formed a research collaboration focused on process development and scale up efforts for the manufacturing of lentiviral vectors.
Subscribe to our email newsletter
The agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners.
bluebird bio president and CEO Nick Leschly said that Genethon has helped identify the genes responsible for hundreds of diseases, developed vectors for gene transfer therapy and established a GMP manufacturing organization.
Genethon chief executive Frederic Reva said that they look forward to being able to combine their expertise with that of bluebird bio and achieve significant improvements in the production of lentiviral vectors for gene therapy through this collaboration.